Willow Biosciences Touts Strong Q3 Results, Continues Its Focus On Biosynthetically Produced Cannabinoids

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) released its third-quarter financial and operating results Monday, revealing it has ended the quarter in a strong financial position, with approximately $35.7 million in cash on hand.

Q3 Financial Summary

  • Net comprehensive income amounted to CA$3.82 million ($3.05 million), compared to a net loss of CA$7.65 in the same period year ago; 
  • Earnings per basic and diluted share were of CA$0.03, versus a loss per share of CA$0.10 in the third quarter of 2020; 
  • Products sales and testing revenue were CA$2,000

Q3 Operational Milestones 

  • On July 20, 2021, Willow announced that it had added cannabinol ("CBN") to its development program. Early indicates that CBN may be effective as a sleep aid or sedative, in addition to other potential health benefits. 
  • On July 20, 2021, the company announced the formation of a senior-level Environmental, Social, and Governance committee to oversee sustainability integration efforts and to provide a direct line from operations to the …

Full story available on Benzinga.com

More Willow Biosciences Touts Strong Q3 Results, Continues Its Focus On Biosynthetically Produced Cannabinoids